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Background: A variety of multimodal treatment options are available for colorectal cancer and many patients want
to be involved in decisions about their therapies. However, their desire for autonomy is limited by lack of
disease-specific knowledge. Visual aids may be helpful tools to present complex data in an easy-to-understand,
graphic form to lay persons. The aim of the present study was to evaluate the treatment preferences of healthy
persons and patients using visual aids depicting multimodal treatment options for colorectal cancer.
Methods: We designed visual aids for treatment scenarios based on four key studies concerning multimodal
treatment of colorectal cancer. The visual aids were composed of diagrams depicting outcome parameters and side
effects of two treatment options. They were presented to healthy persons (n = 265) and to patients with colorectal
cancer (n = 102).
Results: Most patients and healthy persons could make immediate decisions after seeing the diagrams (range: 88% –
100%). Patients (79%) chose the intensive-treatment option in the scenario with a clear survival benefit. In scenarios
without survival benefit, all groups clearly preferred the milder treatment option (range: 78% - 90%). No preference was
seen in the scenario depicting equally intense treatment options with different timing (neoadjuvant vs. adjuvant) but
without survival benefit.
Conclusions: Healthy persons’ and patients’ decisions using visual aids seem to be influenced by quality-of-life aspects
rather than recurrence rates especially in situations without survival benefit. In the future visual aids may help to
improve the management of patients with colorectal cancer.
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Colorectal cancer (CRC) is the second most common
form of cancer in both genders today. The last decades
have shown a rising incidence, while advances in treat-
ment have led to decreasing mortality [1]. Multimodal
treatment strategies have been established and are pres-
ently regarded as standard for many tumor stages. The
wealth of possible treatment options requires a sophisti-
cated planning of the therapeutic approach. Recommen-
dations for the individual treatment of patients are
nowadays often made by an interdisciplinary panel of
specialists based on the staging and pathological results.* Correspondence: marko.kornmann@uniklinik-ulm.de
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reproduction in any medium, provided the orHowever, the relation between the doctor and patients
has changed considerably in recent years due to patients’
increasing desire for autonomy. Many patients want to
be involved in the process of decision-making about
their therapies [2] and already have differentiated ideas
about their therapy stemming from information often
gathered in the internet [3]. However, these ideas may
be unrealistic because patients lack sufficient disease-
specific knowledge and experience with the potential
progression of the disease, whereas physicians may be
misled in regard to patients’ expectations. Both patients
and physicians are forced to make vital decisions in the
face of complex and sometimes confusing data with re-
gard to effectiveness and toxicity of various potential
treatment options.ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Study characteristics
Scenario Reference Disease UICC Stage Mild Therapy Intense Therapy Characteristics
1 [12,13] colon cancer III OP only OP + adjuvant 5-FU survival benefit of intensive therapy
2 [14] colon cancer II + III adjuvant 5 FU adjuvant 5 FU + Oxaliplatin no survival benefit
3 [15-18] rectal cancer I – III OP only OP + short-course radiotherapy no survival benefit
Reference Disease UICC Stage Pre-OP Option Post-OP Option Characteristics
4 [19] rectal cancer II + III preoperative CRT postoperative CRT no survival benefit
OP, operation; CRT, chemoradiotherapy.
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sential to provide patients with information based on
current scientific evidence that is both easy to under-
stand and detailed. In malignant diseases such as breast
or prostate cancer decision aids have been tested to fa-
cilitate the patient’s decision-making process [4-6]. In
colorectal cancer decision aids were used in the process
of screening [7,8]. Only one study so far evaluated deci-
sion aids for palliative colorectal cancer treatment [9].
Therefore, it is presently completely unknown how
healthy persons and patients would decide when con-
fronted with multimodal treatment options in curative
settings of colorectal cancer. In contrast to decision aids
















Figure 1 Visual aid illustrating two treatment scenarios for patients w
[12,13]. The results of an operation (OP) alone (A) are shown as mild treat
chemotherapy (CHT) (B) are shown as intense treatment on the right. The
representing% or events. The relative incidence of local recurrence and dis
important undesired events in the two lower quadrants. The difference in
dotted circle followed by a statement about overall survival benefit. To bet
several criteria applied to one patient (e.g., nausea and diarrhea), the first c
foreground with the sign (X) in the appropriate color.recently designed visual aids for several scenarios of
multimodal potentially curative treatment options of
colorectal cancer which could be used by the physician
to present the outcome and side effects of various treat-
ment options to the patient [10,11]. The aim of the
present study was to evaluate the treatment preferences
of healthy persons and patients for potentially curative
multimodal treatment options in colorectal cancer using
these visual aids.
Methods
Selection of studies for visual aids
Four key studies of colorectal cancer influencing treat-









efit in B: 5 %
ith UICC stage III colon cancer based on the published data
ment on the left, and the results of an OP plus adjuvant 5-FU
illustrations are based on 4 quadrants showing 100 squares
tant metastasis are displayed in the two upper quadrants and
recurrence of the two treatment options is summarized in the central
ter differentiate the criteria, each is represented in a different color. If
riterion is shown as background color. Further criteria are shown in the
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mized controlled trials (Table 1). In scenarios 1 – 3, a
mild therapeutic option consisting of an operation alone
or an operation with adjuvant mono-chemotherapy was
presented in comparison with a more intensive thera-
peutic option consisting of an operation with mono-
chemotherapy, double-chemotherapy, or radiation
[12,14,15]. In scenario 4, the results of two equally in-
tense options were presented comparing neoadjuvant
chemoradiotherapy with adjuvant chemoradiotherapy in
rectal cancer [19].
Design of the visual aids
There exists a huge literature about how to present in-
formation to healthy persons and patients [20-22]. One
of the key findings was that graphical presentation in-
cluding frequencies may be most appropriate to
present results of clinical trials [23]. Our designed vis-
ual aids depicted separately the results of two treat-
ment options evaluated in a randomized controlled
trial according to therapeutic outcome and side-effects.
They were presented as graphs as described previously
[10,11]. This was achieved by four-colored square dia-
grams, each consisting of 100 small squares (four
quadrants), representing a total of 100 patients or
100% (Figure 1). One colored square stands for oneA

















Figure 2 Visual aid illustrating two adjuvant treatment scenarios for p
an operation (OP) plus 5-FU chemotherapy (CHT) are shown as mild treatm
combination CHT are shown as intense treatment (B) on the right. The rela
displayed in the two upper quadrants and important undesired events in t
treatment options is summarized in the central dotted circle followed by aevent in a patient; a cross means the coincidence of
two events in one patient. The two quadrants on the
left side show the first treatment option, while the sec-
ond option is displayed in the quadrants on the right
side. The two upper quadrants show the outcome
results, such as mortality, local recurrence rates and
distant metastases. The two lower quadrants display
possible side effects. Survival differences between the
two therapy arms are presented separately in the mid-
dle (Figure 1).
Out of the recommended quality criteria for patient
decision aids published [20,24] our visual aids fulfilled
several important criteria including systematic develop-
ment process [10,11], providing information about
options, presenting probabilities, disclosing conflicts of
interest, balancing the presentation of options, using
plain language, and basing information on up to date
scientific evidence. During presentation it was also pos-
sible to clarify values and to communicate with the
presenter. There was no conflict of interest. In constrast
to the requirement of decision aids our visual aids are
not publicly available.
Feasibility testing using healthy persons
After establishing the graphs as described above and
previously reported [10,11], a pilot experiment wasB
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atients with UICC stages II and III colon cancer [14]. The results of
ent (A) on the left, and the results of an OP plus 5-FU and oxaliplatin
tive incidence of death, local recurrence and distant metastasis are
he two lower quadrants. The difference of recurrence of the two
statement about overall survival benefit.
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preferences of healthy persons with regard to the treat-
ment options were also evaluated. Thus, the visual aids
of the four scenarios were presented to 213 healthy
persons as a powerpoint presentation in an auditorium
after a 30-minute lecture about colorectal cancer. Each
participant marked his/her preferred treatment option
on a form using a pencil directly after the presentation
of each study. They had the option to vote for treat-
ment A or treatment B. In addition, participants had
the possibility to mark a third option, “I don't know”,
if they were not able to make a decision immediately.
This experiment was carried out with the support of
several social clubs (Landfrauen and protestant church)
in the area which organized the recruitment and trans-
port of the volunteers to the auditorium.
Evaluation of the visual aids by patients
After demonstrating feasibility an ethics request was
filed as a precondition for the following study involv-
ing colorectal cancer patients. The study was
approved by the ethics committee of the University of
Ulm (no. 141/08).
After giving written informed consent, patients with




















Figure 3 Visual aid illustrating two treatment scenarios for patients w
results and side effects [15-18]. The results of the “new” operation (OP) a
treatment (A) on the left, and the results of the “new” OP plus neoadjuvan
(B) on the right. The relative incidence of death, local recurrence and dista
undesired events in the two lower quadrants. The difference of recurrence
circle followed by a statement about an overall survival benefit.the authors (J.V.) about their treatment preferences after
being shown the colored print-out diagrams wrapped in
transparent foil. Patients with colorectal cancer were
asked to participate either during an outpatient visit at
the time of follow-up 6 to 24 months after surgery (n =
52) or during inpatient treatment approximately 10 days
following surgery of primary colorectal cancer (n = 50).
An additional 52 healthy persons of the authors’ milieu
were also questioned individually to rule out potential
differences with regard to the mode of presentation
(group vs. individual). Similar to the healthy persons in
the auditorium, participants had the option to vote for
treatment A or treatment B. They could also mark the
third option, “I don't know”, if they were not able to
make a decision during the individual presentation. All
participants were requested to fill out a demographic
questionnaire before the presentation.
Results
Design of the visual aids
The results of four prospective, randomized controlled
trials [12,14,15,19] comparing two treatment options
were presented as graphic scenarios displaying outcome
parameters (mortality, recurrence rates, survival) and
side effects (Figures 1, 2, 3, 4). In scenarios 1 – 3, a mildio 3
B






te in A = B
ith UICC stages I to III rectal cancer based on the published
lone (total mesorectal excision technique) are shown as mild
t short-course (5x5 Gy) radiotherapy are shown as intense treatment
nt metastasis are displayed in the two upper quadrants and important
of the two treatment options is summarized in the central dotted
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therapeutic option, while two equally intense options
with different timing (neoadjuvant vs. adjuvant) were
presented in scenario 4. The characteristics of the sce-
narios and related studies are summarized in Table 1,
while the visual aids are shown in Figures 1, 2, 3, 4.Groups of participants
In a pilot experiment the prepared visual aids were pre-
sented to 213 healthy persons as a powerpoint presenta-
tion in an auditorium after a 30-minute lecture about
colorectal cancer. Demonstrating the feasibility of our
visual aids in a next step patients with colorectal cancer
(n = 102) were questioned individually. One of the
authors (J.V.) interviewed patients either during
inpatient treatment following an operation (n = 50) or
during an outpatient visit within the follow-up program
(n = 52). The visual aids were presented as colored print-
out diagrams wrapped in transparent foil. In addition,
another 52 healthy persons were questioned in this indi-
vidual fashion to rule out a possible influence of the
mode of presentation (auditorium vs. individual). The
demographics of the participating groups are summar-






















Figure 4 Visual aid illustrating two equally intense treatment scenario
results of neoadjuvant chemoradiotherapy followed by an operation (OP) a
OP followed by adjuvant chemoradiotherapy are shown as post-operative
treatment in option A, only 72% of the patients underwent additional adju
relative incidence of death, local recurrence and distant metastasis are disp
long-term side effects in the two lower quadrants. The difference of recurr
circle followed by a statement about an overall survival benefit.Decisions of the groups
The participants generated a total of 1468 preferences
when shown the 4 scenarios – 408 patient preferences
and 1060 preferences of healthy persons. The results for
the three groups are summarized in Table 3. There were
no differences in the decisions between the in- and out-
patients (data not shown).
The first scenario (Figure 1) compared an operation
alone with an operation and adjuvant mono-
chemotherapy in colon cancer [12]. The results were
characterized by a 5% survival advantage in the second
group. Furthermore, an obviously lower rate for local re-
currence and distant metastasis could be shown. Side
effects were only documented for the chemotherapy
group. The majority of patients and healthy persons
questioned individually chose the intensive treat-
ment (77% and 71%, respectively). Only half of the
healthy persons from the auditorium group chose this
option (49%).
The second scenario (Figure 2) displayed two adjuvant
treatment options for colon cancer, comparing 5-FU
mono-chemotherapy with 5-FU and oxaliplatin double-
chemotherapy [14]. Despite better control of tumor re-
currence by the intensive option, survival rates in the











s for patients with UICC stages I to III rectal cancer [19]. The
re shown as pre-operative option (A) on the left, and the results of an
option (B) on the right. While all patients underwent neoadjuvant
vant treatment, depending on the pathological tumor stage. The
layed in the two upper quadrants and important undesired acute and
ence of the two treatment options is summarized in the central dotted





n = 102 n = 52 n = 213
Age (years) 20-29 24 (11%) 2 (4%) 1 (1%)
30-39 6 (3%) 3 (6%) 2 (2%)
40-49 26 (12%) 4 (8%) 10 (10%)
50-59 59 (28%) 13 (25%) 17 (17%)
60-69 51 (24%) 13 (25%) 29 (28%)
>69 47 (22%) 17 (33%) 43 (42%)
Gender female 155 (73%) 25 (48%) 41 (40%)
male 58 (22%) 27 (52%) 61 (60%)
Education secondary general school 114 (54%) 35 (67%) 65 (64%)
intermediate school 47 (22%) 8 (15%) 17 (17%)
grammar school 27 (13%) 2 (4%) 7 (7%)
university 21 (10%) 7 (13%) 12 (12%)
university + doctoral thesis 4 (2%) 0 (0%) 1 (1%)
Relation of education to healthcare services no relation 154 (72%) 42 (81%) 95 (93%)
some relation 7 (3%) 4 (8%) 3 (3%)
relation, no treatment of patients 29 (14%) 4 (8%) 2 (2%)
patient treatment, no physician 17 (8%) 1 (2%) 1 (1%)
physician 6 (3%) 1 (2%) 1 (1%)
Relation of work to healthcare services no relation 168 (79%) 44 (85%) 84 (82%)
some relation 7 (3%) 3 (6%) 9 (9%)
relation, no treatment of patients 22 (10%) 3 (6%) 6 (6%)
patient treatment, no physician 15 (7%) 1 (2%) 2 (2%)
working in a surgical field 1(0,5%) 1 (2%) 0 (0%)
non-surgical field - 0 (0%) 1 (1%)
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showed a strong preference for the mild treatment option,
irrespective of the mode of presentation (range 81% - 90%,
Table 3).
In the third scenario (Figure 3), the operation alone in-
volving a total mesorectal excision (TME) was compared
with short-course radiotherapy (5x5 Gy) followed byTable 3 Results of test person’s decisions
Patients Healthy Person
n = 102
Treatment option Treatment op
Scenario Mild Intense No decision Mild In
1 [12,13] 23 (23%) 79 (77%) 0 (0%) 15 (29%) 37
2 [14] 81 (80%) 19 (18%) 2 (2%) 46 (88%) 6
3 [15-18] 84 (82%) 12 (12%) 6 (6%) 42 (81%) 4
Scenario Pre-OP Post-OP No decision Pre-OP Po
4 [19] 42 (41%) 57 (56%) 3 (3%) 23 (44%) 24TME in rectal cancer [15]. The intensive option showed
better local control and a somewhat lower frequency of
distant metastases, but no effect on survival. The inten-
sive option was associated with more side effects. Similar
to scenario 2, all groups preferred the mild treatment
option, regardless of the form of presentation (range
78% - 82%, Table 3).s (individually asked) Healthy Persons (in auditorium)
n = 52 n = 213
tion Treatment option
tense No decision Mild Intense No decision
(71%) 0 (0%) 102 (48%) 105 (49%) 6 (3%)
(12%) 0 (0%) 192 (90%) 9 (4%) 12 (6%)
(8%) 6 (11%) 166 (78%) 21 (10%) 26 (12%)
st-OP No decision Pre-OP Post-OP No decision
(46%) 5 (10%) 60 (28%) 138 (65%) 15 (7%)
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treatment options comparing neoadjuvant chemora-
diotherapy with adjuvant chemoradiotherapy in rectal
cancer were presented [19]. The first option included all
patients in the neoadjuvant treatment, whereas the
second option included only 70% of the patients -
depending on the tumor stage – who received adjuvant
chemoradiotherapy. The advantage of the neoadjuvant
option was the lower rate of local recurrence and distant
metastasis (Figure 4). The groups of patients and healthy
persons questioned showed no preference, choosing the
adjuvant treatment option in 65% to 46%, respectively.
There was no difference between the preference of any
group.
Discussion
Three main forms of patient-physician relationships have
been described [2]: First, the era of parternalism - doctor
served as the guardian; second, the era of informed con-
sent; and third, the era of shared-decision-making.
Today many patients want to be well informed and de-
mand to take an active role in the planning of their
treatment reflecting a shift in the patient’s role in
decision-making from the passive bystander to an active
participant [2,3,6]. However, patients’ desire for auton-
omy is impaired by a lack of disease-specific knowledge
and by the growing complexity of treatment options
which have recently become available, especially in can-
cer therapy. Guidelines have been developed by expert
consensus to give recommendations for a therapy or
combination of therapies according to the disease stage
to support medical professionals in their recommenda-
tions. However, since guidelines are standardized, they
may not consider the patient’s individual preferences
and thoughts about life planning. To be able to partici-
pate in the individual decision-making process it is es-
sential to provide information for the patients based on
current scientific evidence that is both easy to under-
stand and detailed. No studies about the use of decision
aids in neoadjuvant or adjuvant treatment of potentially
curative colorectal cancer have been published to date
[8]. Therefore, in analogy to decision aids we designed
visual aids for neoadjuvant and adjuvant treatment of
colorectal cancer depicting various therapy options. The
design of our visual graphs basically followed the basic
recommendations for decision aids standards except
public availability [20,24]. Our aim was to evaluate the
treatment preferences of patients for these multimodal
treatment options using visual aids.
To test the feasibility of the visual aids the four
designed graphs were presented to 213 healthy persons
in an auditorium after a lecture about colorectal cancer.
These preliminary results demonstrated that our visual
aids were feasible, because most participants could makedecisions immediately. Evaluation of these results further
revealed that healthy persons generally preferred the
milder treatment options. These options were often not
recommended by our German guideline [25]. In order to
rule out that healthy persons decide different from
patients suffering from colorectal cancer facing a poten-
tially lethal disease the second part of our study was car-
ried out. Patients were asked individually for their
preferences. We again asked healthy persons in an indi-
vidual manner to rule out effects with regard to the
mode of presentation.
Our results demonstrated that most patients and
healthy persons can make a decision after being shown
the visual aids. As expected the majority of patients
(77%) and healthy persons (71%) chose the intensive
treatment option in scenario 1 demonstrating a survival
benefit when asked individually. We do not know why
only 49% of healthy persons questioned in the auditor-
ium chose the option accompanied with the survival
benefit. It is possible therefore that the presenter and
mode of presentation may have influenced the decision
making to some extent, one possible limitation of our
study. It is also possible that the lecture about colorectal
cancer might have affected their opinion.
In contrast, the evaluation of the treatment choices
without effect on overall survival revealed that the ma-
jority of the patients and healthy persons preferred the
mild treatment options (78%-90%) independent of the
mode of presentation (scenarios 2 and 3). When looking
at the graphs of the visual aids these preferences seem
not really surprising. However, they clearly contradict
the opinion of specialists justifying intensive treatment
by a sole reduction of recurrence rates and the present
German guideline recommendations [25]. Our results
suggest that participants - patients and healthy persons -
placed more emphasis on quality-of-life aspects than on
recurrence rates in decisions without difference in sur-
vival. This was not surprising to us and confirmed our
previous results in healthy persons [10,11,26].
The fourth scenario depicted two equally intense
options comparing different modes of application
(neoadjuvant vs. adjuvant) in rectal cancer. The advan-
tage of the neoadjuvant option is the significantly lower
rate of local recurrence. This option is therefore recom-
mended presently by the treatment guidelines and most
physicians [25]. However, patients and healthy persons
did not show a preference for the neoadjuvant therapy
(28%-41%). Instead, no difference in the treatment pre-
ference was observed between the neoadjuvant and adju-
vant options presented. This is probably related to the
lack of a survival benefit and the possibility to avoid che-
moradiotherapy at all when choosing the other option
(adjuvant). While all patients received neoadjuvant che-
moradiotherapy, only 72% of the patients received
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patients had tumors of lower stage that did not require
multimodal treatment after final pathological examin-
ation [19].
In summary, our results showed: first, that patients
and healthy persons can make decisions about presented
multimodal treatment options using visual aids; second,
that the decisions of patients and healthy persons are
equal and independent of the mode of presentation
when comparing mild versus intensive treatment with-
out survival benefit; third, in decisions with survival
benefit, patients and healthy persons prefer the benefi-
cial option, but this may depend on the mode of presen-
tation; and fourth, there is no preference for “equally”
intense options without survival benefit.
Conclusions
We conclude from our results and experience gained
during the project that patients’ decisions are primarily
influenced by quality-of-live aspects and overall survival,
often contrasting treatment recommendations made by
specialists and national guidelines. Visual aids may be
reasonable tools in the management of colorectal cancer
patients in the future. They may be helpful to supply
patients with additional information about the results
and side effects of various disease-specific treatment
options thereby increasing patients’ knowledge about the
disease and thus gaining more confidence in the treat-
ment and its consequences.
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